Guy Goldberg, Redhill’s The leading business officer today presents a business update in the forum of fair director of European life sciences
Update covers:
- Last Last Link of RHB-102[1] to Hyloris (Euronext Brussels: HYL) in a potential $ 60 million Plus the honorary deal
- Starting Phase 2 clinical study funded by Bayer[2] In combination with Bayer’s darolutamide (ETR: Bayn) in advanced prostate cancer
- The status of US government -backed pipeline programs and expected 2025 catalysts
- Important trade progress with TaliciaABOUT:
- Additional marketing authorization applications in new markets assessed
- The following discussions focused on lowering significant goods costs (Cogs)
- Inclusion as the first line option for the treatment of H. pylori infection at American College of Gastroenterology (ACG) Clinical Instruction
- HumanityABOUTCoverage of Plan of Part D adds access to more than eight million extra medical lives, with no previous therapeutic steps or authorization
- Exceeded 100,000 recipe pistols, while maintaining position as brand #1 described by gastroenterologists
- Land Guarantee Program Started – Minimum Refunds claimed
- New data on the most appropriate routine three times a day (TID) “Breakfast, Lunch and Dinner” published in the clinical pharmacology newspaper that support FDA SNDA’s prior approval for TID dosage
- License outside, approval and starting to UAE
Raleigh, nc AND Tel-Aviv, Israel, 27 February 2025 / Prnewswire/ – Redhill Biopharma Ltd. (Nasdaq: RDHL) (“Reddish“Or” company “), a biofarmic specialty company, announced today the introduction of a business update from Guy Goldberg, Redhill’s The main business officer, underlining the latest important corporate activity, R&D advances and commercial progress with Talicia, at the 18th annual CEO forum of European Sachs Associates Life Sciences Bureh.
“We have had a very positive start by 2025, making significant progress on numerous fronts. We have just announced the Licensing of RHB-102 in Hyloris, in a valid agreement up to $ 60 million at possible historical payments plus additional revenue royalties. We have recently announced the beginning of a Phase 2 clinical study funded by Bayer for Opaganib in combination with Bayer’s Darolutamide for advanced prostate cancer, for which there are very limited opportunities. This is in addition to the numerous R&D programs of the Academy supported by the Academy with the Academy with the leading potential catalysts of 2025, including for the protection of damage from radiation, oncology and various indications of pandemic readiness, ” stated Guy Goldberg, Redhill’s Main business official. “The trade team is working just as hard for cement, and relying on the position of Talicia as the number one brand H. Pylori therapy. Depending on the successful conclusion of our ongoing discussions, we expect to significantly reduce Cogs of Talicia, increasing directly. Other recent achievements include Humana Part D victory, adding eight million more media lives; Inclusion as the first line option in the new ACG instruction; and the approval of FDA SNDA to move to a more appropriate TID dose. There are also opportunities for Talicia to open in new markets outside the US and the end trade in the United Arab Emirates, and we are evaluating additional marketing authorization applications in other countries. Talicia has now exceeded the history of 100,000 recipes, our land guarantee program, with the minimum alleged refunds, reflects a positive experience, and now, with the new possible markets on the horizon, we are optimistic about the future for Talicia and the value it can offer. “
The presentation was only available for the participants registered.
About Redhill Biopharma
Redhill Biopharma Ltd (Nasdaq: RDHL) is a company specialty biofarmic mainly focused on US development and commercialization of medicines for gastrointestinal diseases, infectious diseases and oncology. Redhill promotes gastrointestinal medicine TalicABOUT, on the treatment of Helicobacter pylori (H. pylori) adult[3]. Key Clinical Development Programs of the Late Phase of Redhill include: (i) Opaganib (ABC294640)A first-grade selective inhibitor, orally administered Kinase-2 (SPHK2) with anti-cancer, anti-inflammatory and antiviral activity, aiming at numerous indications with the US government and academic cooperation for development of radiation and chemical exposure indications such as GI-ARA (GI-ARA). for Covid-10, and ANE SPOSTOUST SPOSTROM, and Acute Sposte combination with Bayer’s darolutamide; (ii) RHB-107 (upamostat), a large-acting, host-directed serine proteinase inhibitor, with potential for pandemic readiness, is in the development of the late phase as a treatment for non-spitting-spitting-19 symptomatic and is also aiming for many other cancers and gastrointestinal inflammatory diseases; (iii) RHB-102now partnership with Hyloris for development and commercialization around the world outside North AmericaWith possible submission to the UK for chemotherapy and radiotherapy caused nausea and vomiting, positive results from a phase 3 study of acute and gastritis gastroenteritis and positive results from a phase 2 study for IBS-D; (iv) RHB-104with positive results from a first stage 3 study of Crohn’s disease; and (v) RHB-204A 3-phase phase program for nontronare mycobacteria (NTM) pulmonary disease.
More information about the company is available at www.redhillbio.com / x.com/redhillbio.
The statements forward in search
This press release contains “future statements” in the sense of the act of reform of the securities of the 1995 property securities and can discuss investment opportunities, shares analysis, financial performance, investor relationships and market trends. Such statements can be preceded by the words “target”, “May”, “do”, “plans”, “hosts”, “forecasts”, “projects”, “forecasts”, “assessments”, “goals”, “hope”, “potential” or involve, “among others”, statements regarding arrangements and possible relationships with Hyloris. Future statements are based on certain assumptions and subject to the various known and unknown risks and ambiguities, many of which are beyond the control of the company and cannot be predicted or quantified, and consequently, the actual results may differ materially from those expressed or implied by such statements. Such risks and uncertainties include, without limitations: the risk that the company will not benefit from the agreement with Hyloris as it was currently provided; Company’s ability to maintain compliance with NASDAQ capital market requirements; The risk that the addition of new products that generate income or license transactions will not happen; The risk of current uncertainty regarding the research and development funds of the US government and that the US government has no obligation to continue to support the development of our products and be able to cease such support at all times; The risk that acceptance in the RNCP product development pipeline or other government and non -governmental development programs will not guarantee continuous development or that such development will not end or successful; The risk that the FDA will disagree with the proposed company development plans for its programs; The risk that observations from pre -clinical studies are not indicators or predictors of results in clinical evidence; The risk that company development programs and studies may not be successful and, even if they are successful, studies and such results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional studies may be required; market risk and other conditions and that the company will not successfully commercialize its products; as well as the risks and uncertainties associated with (i) the beginning, time, progress and results of the research, production, pre-clinical studies of the company, clinical studies and other therapeutic candidate development efforts, and the time of commercial commercial starting and those that may acquire or develop in the future; (ii) the company’s ability to advance its therapeutic candidates in clinical evidence or to successfully complete its pre-clinical studies or clinical evidence or the development of any necessary commercial diagnostics; . (IV) Production, clinical development, commercialization and acceptance of the company’s therapeutic candidates and Talicia®; (v) Company’s ability to successfully commercialize and promote Talicia®; (vi) the company’s ability to create and maintain corporate cooperation; (vii) the company’s ability to buy approved products for marketing at the US that achieve trade success and build their own marketing and commercialization skills; (VIII) interpretation of the properties and characteristics of the therapeutic candidates of the company and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical evidence; (IX) implementation of the company’s business model, strategic plans for its business and therapeutic candidates; (X) Defense Area The company is able to create and maintain for intellectual property rights that cover its therapeutic candidates and its ability to operate its business without violating the intellectual property rights of others; (XI) the parties from which the company licenses its intellectual property by not paying their obligations to the company; (XII) Company expenditure estimates, future income, capital requirements and additional financing needs; (XIII) Effect of patients suffering unfavorable experiences using investigative medicines under the expanded company entry program; (XIV) competition from other companies and technologies within the company industry; and (XV) date of start and start of employment of executive managers. The most detailed information about the company and the risk factors that may influence the realization of future statements are set out in the company’s registrations with the Insurance and Exchange Commission (SEC), including the company’s annual report on form 20-F submitted to the SEC in April 8 2024. All future statements included in this press release are made only from the date of this press release. The company receives no obligation to update any written or future written statement, either as a result of new information, future events or otherwise, unless required by law.
Company contact:
Fry
Main Corporate and Business Development Officer
Redhill Biofarma
+972-54-6543-112
[email protected]
Category: Corporation
[1] RHB-102 is a new investigative drug, not available for commercial distribution.
[2] Opaganib is a new investigative drug, not available for commercial distribution.
[3] TalicABOUT (Magnesium Omeprazol, Amoxicillin and Rifabutin) indicated for the treatment of H. Pylori infection in adults. For full description information, see: www.talicia.com.
Logo: https://mma.prnewswire.com/media/1334141/redhill_biopharma_logo.jpg
Source Redhill Biopharma Ltd.